Reaktionsgleichung
[CH3:1][S:2]([C:5]1[CH:6]=[C:7]2[C:11](=[CH:12][CH:13]=1)[NH:10][CH:9]=[CH:8]2)(=[O:4])=[O:3].[C:14]([O:18][C:19]([N:21]1[CH2:26][CH2:25][C@@H:24]([O:27][C:28]2[CH:29]=[N:30][C:31](Cl)=[CH:32][CH:33]=2)[C@H:23]([F:35])[CH2:22]1)=[O:20])([CH3:17])([CH3:16])[CH3:15]>>[C:14]([O:18][C:19]([N:21]1[CH2:26][CH2:25][C@@H:24]([O:27][C:28]2[CH:29]=[N:30][C:31]([N:10]3[C:11]4[C:7](=[CH:6][C:5]([S:2]([CH3:1])(=[O:4])=[O:3])=[CH:13][CH:12]=4)[CH:8]=[CH:9]3)=[CH:32][CH:33]=2)[C@H:23]([F:35])[CH2:22]1)=[O:20])([CH3:17])([CH3:15])[CH3:16]Komponenten
3
Versuchsvorschrift
The title compound was prepared by following the similar procedure as described in Example-1 by using 5-(methylsulfonyl)-1H-indole (intermediate-21) and trans(±)-tert-butyl-4-((6-chloropyridin-3-yl)oxy)-3-fluoropiperidine-1-carboxylate (intermediate-63) (0.220 g, 37%).
Quellen und Nachweise
- ORD-Eintrag
- ord-8a75adf4647046bcac4ed8ea3ef395e2
- Quelldatensatz
- uspto-grants-2015_04
- Patentnummer
- US09000175B2
Verknüpfte Notizen
Wird geladen…